Processing

Please wait...

Settings

Settings

Goto Application

1. RU0002660341 - METHOD FOR PREVENTING MENSTRUAL DISORDERS IN GIRLS

Office Russian Federation
Application Number 2016152782
Application Date 30.12.2016
Publication Number 0002660341
Publication Date 05.07.2018
Grant Number
Grant Date 05.07.2018
Publication Kind C2
IPC
G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
A61K 31/59
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
59Compounds containing 9,10-seco-cyclopentahydro- phenanthrene ring systems
A61P 15/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15Drugs for genital or sexual disorders; Contraceptives
08for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
CPC
A61K 9/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
A61K 31/59
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
C12Q 1/6804
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6804Nucleic acid analysis using immunogens
C12Q 1/6827
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6813Hybridisation assays
6827for detection of mutation or polymorphism
C12Q 1/6858
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6844Nucleic acid amplification reactions
6858Allele-specific amplification
C12Q 1/686
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6844Nucleic acid amplification reactions
686Polymerase chain reaction [PCR]
Inventors Денисова Тамара Геннадьевна (RU)
Герасимова Людмила Ивановна (RU)
Денисов Мелсик Спартакович (RU)
Denisova Tamara Gennadevna (RU)
Gerasimova Lyudmila Ivanovna (RU)
Denisov Melsik Spartakovich (RU)
Title
(EN) METHOD FOR PREVENTING MENSTRUAL DISORDERS IN GIRLS
(RU) СПОСОБ ПРОФИЛАКТИКИ НАРУШЕНИЙ МЕНСТРУАЛЬНОЙ ФУНКЦИИ У ДЕВУШЕК
Abstract
(EN)
FIELD: medicine. SUBSTANCE: invention relates to the field of medicine, in particular to gynecology, and is intended to prevent menstrual disorder in patients. Level of vitamin D in the blood serum is determined. With its content < 16.2 ng/ml, DNA isolation and genotyping of genes are performed GC rs2282679, CYP2R1 rs2060793, VDR rs2228570. When genotypes are identified C/C VDR rs2228570 and/or A/C GC rs2282679 vitamin D at a dose of 4,000 U/day is prescribed. When genotypes are identified T/T VDR rs2228570, T/T CYP2R1 rs2060793 and A/A GC rs2282679 2,000 U/day for 9 months is prescribed. EFFECT: invention provides a differential choice of the optimal dose of vitamin D. 1 cl, 3 tbl, 3 ex

(RU)
Изобретение относится к области медицины, в частности к гинекологии, и предназначено для профилактики нарушений менструальной функции у пациенток. Определяют уровень витамина D в сыворотке крови. При его содержании <16,2 нг/мл проводят выделение ДНК и генотипирование генов GC rs2282679, CYP2R1 rs2060793, VDR rs2228570. При выявлении генотипов С/С VDR rs2228570 и/или А/С GC rs2282679 назначают витамин D в дозе 4000 ЕД/день. При выявлении генотипов Т/Т VDR rs2228570, Т/Т CYP2R1 rs2060793 и А/А GC rs2282679 назначают 2000 ЕД/день в течение 9 месяцев. Изобретение обеспечивает дифференцированный выбор оптимальной дозы витамина D. 3 табл., 3 пр.